A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers
Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 1
2002-08-01
The objective of this study is to compare the levels of the hormones norelgestromin,
norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers
administered ORTHO EVRA® (a transdermal contraceptive patch) and CILEST® (an oral
contraceptive). The open-label treatment phase of the study consists of two 28-day cycles of
one treatment, a washout period of 28 days, and crossover to two 28-day cycles of the other
treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.